3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
13
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma
1
Refractory Solid Tumors
1
Liposarcoma
1
HR+HER2- Breast Cancer
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
eribulin
×
90 days
×
Clear all
No trials found.